Acute treatment and rapid treatment of headache using anti-CGRP antibodies
AssigneeH. Lundbeck A/S
InventorsRoger K. Cady, Jeffrey T.L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
Life of this patent
Estimating the term…
Abstract
Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
Claims31
A method of acute treatment of migraine in a patient in need thereof, the method comprising intravenously administering to the patient:
- (A) about 100 mg or about 300 mg of a monoclonal antibody comprising:
- (a) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 224, SEQ ID NO:
- 226, and SEQ ID NO:
- 228, respectively, and
- (b) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 204, SEQ ID NO:
- 206, and SEQ ID NO:
- 208, respectively;
- and
- (B) one or more acute migraine medications,
- wherein the administering begins while the patient is experiencing a headache, and wherein the administering is followed by preventive treatment once every three months using about 100 mg or about 300 mg of said monoclonal antibody.
A method of reducing the occurrence of migraine in a patient in need thereof, the method comprising intravenously administering to the patient, about 100 mg or about 300 mg of a monoclonal antibody comprising:
- (A) a variable light chain polypeptide comprising light chain complementary determining region (CDR) 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 224, SEQ ID NO:
- 226, and SEQ ID NO:
- 228, respectively, and
- (B) a variable heavy chain polypeptide comprising heavy chain CDR 1, 2, and 3 polypeptide sequences of SEQ ID NO:
- 204, SEQ ID NO:
- 206, and SEQ ID NO:
- 208, respectively,
- wherein the administering begins while the patient is experiencing a headache, and wherein the administering is followed by administration of about 100 mg or about 300 mg of said monoclonal antibody once every three months.
Dependencies are inferred from the claim text.